Hybio Pharmaceutical Co Ltd

Hybio Pharmaceutical Co Ltd operates with a capital structure that is highly leveraged, as evidenced by a debt-to-equity ratio of 3.12. The company's liquidity position is rated as medium, with a current ratio of 0.29, indicating that it has less than one unit of current assets for every unit of current liabilities. The company's price-to-book ratio of 33.81 suggests that the market values the company significantly higher than its book value, which may reflect expectations of future growth or intangible assets not captured in the balance sheet. In terms of profitability, Hybio's return on equity (ROE) of 5.96% is below the typical benchmark for pharmaceutical companies, which often aim for ROE above 10%. The return on assets (ROA) of 1.16% further indicates that the company is not efficiently utilizing its assets to generate profits. The gross profit margin of 56.4% is in line with industry norms, but the operating margin of 7.14% is relatively low, suggesting that the company is facing significant operating expenses or cost pressures. Geographically, Hybio's revenue is concentrated in China, with no disclosed international operations in the provided data. The company's revenue concentration in a single market exposes it to regulatory, economic, and geopolitical risks specific to China. The absence of diversified revenue streams may limit its ability to buffer against domestic market fluctuations. Hybio's growth trajectory appears to be modest, with the company's revenue of 966.35 million CNY in the latest period. The company's capital expenditures of -234.35 million CNY indicate a reduction in investment in physical assets, which may signal a strategic shift or financial constraints. The free cash flow of -179.92 million CNY is negative, suggesting that the company is not generating enough cash from operations to cover its capital expenditures. The risk assessment for Hybio highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations or invest in growth opportunities without external financing. The low dilution risk is attributed to the absence of significant dilutive events in the recent financial data. Recent events and filings for Hybio include the latest actual EPS of 0.04 CNY and revenue of 966.35 million CNY, as reported by analysts. These figures provide a snapshot of the company's recent performance but do not indicate any significant changes in strategy or operations.